Request Demo
Last update 12 Oct 2026
Ruzaltatug rezetecan
Last update 12 Oct 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms 瑞康芦泽妥塔单抗, SHR A2009, SHR-A2009 + [1] |
Target |
Action antagonists, inhibitors |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (United States), Breakthrough Therapy (China) |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Sequence Code 1047126308H
Source: *****
Sequence Code 1047126309L
Source: *****
Related
13
Clinical Trials associated with Ruzaltatug rezetecanNCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
NCT07414953
A Phase Ib Study of the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of HS-10504 Combined Therapy in Advanced Non-small Cell Lung Cancer Patients
NCT07183189
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
100 Clinical Results associated with Ruzaltatug rezetecan
Login to view more data
100 Translational Medicine associated with Ruzaltatug rezetecan
Login to view more data
100 Patents (Medical) associated with Ruzaltatug rezetecan
Login to view more data
100 Deals associated with Ruzaltatug rezetecan
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | China | 29 Jul 2026 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 30 Oct 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 3 | China | 29 Nov 2024 | |
| Resectable Lung Non-Small Cell Carcinoma | Phase 2 | China | 30 Oct 2026 | |
| Breast Cancer | Phase 2 | China | 20 Feb 2024 | |
| metastatic non-small cell lung cancer | Phase 2 | - | 01 Oct 2023 | |
| Solid tumor | Phase 2 | - | - | |
| EGFR positive non-small cell lung cancer | IND Approval | China | 20 Jul 2026 | |
| Advanced Lung Non-Small Cell Carcinoma | IND Approval | China | 10 Feb 2026 | |
| Advanced cancer | IND Approval | China | 20 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Non-Small Cell Lung Cancer EGFR-mutant | 12 | lxewcuthcu(atfumecwal) = ozlnwfuxln bnwbirqocs (vccdcmbnbx ) View more | Negative | 12 Sep 2026 | ||
izksijynnh(zwrsqdozig) = igbbqgwggw kuaoxshwyq (etvygtvtmx ) View more | |||||||
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR-mutated | 130 | ypdkaiskbc(ssjamefseq) = lugittilqc pqdqgblpay (inbnqrrcig, 75.7 - 98.1) View more | Positive | 25 Mar 2026 | ||
ypdkaiskbc(ssjamefseq) = jjafdxbmus pqdqgblpay (inbnqrrcig, 76.6 - 95.6) View more | |||||||
NCT05114759 (ESMO2024) Manual  | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 103 | anxgldtbfw(gqmivuhumy) = 56.3% of 103 pts, with all occurring in ≥5% being hematotoxicities. tjwqkvoqgl (ogrzaqnxat ) View more | Positive | 14 Sep 2024 | |
(Prior PBC treated) | |||||||
Phase 1 | HR-positive/HER2-low Solid Tumors EGFR mutations | 42 | mxxtmytfed(qsvauamqlv) = tzjvjakbst gsifaplcyu (ukaifdvvoo ) View more | Positive | 23 Oct 2023 | ||
(1.5 mg/kg) | ozigonmrhp(msauidbmsc) = weiehoujnd ujikfxkcao (pnxxzfetso ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free